雷珠单抗对缺血型与非缺血型BRVO继发黄斑水肿患者黄斑区不同区域血流密度的影响OA

AIM:To investigate the effect of ranibizumab on blood flow density in different regions of the macula in patients with macular edema(ME)secondary to ischemic and non-ischemic branch retinal vein occlusion(BRVO). METHODS:This retrospective study enrolled patients with BRVO-ME who were treated at the hospital from September 2019 to March 2021.Patients were divided into ischemic and non-ischemic groups based on fundus findings.All patients received intravitreal injections of ranibizumab once monthly for three consecutive months.Best corrected visual acuity(BCVA),central macular thickness(CMT),and macular blood flow density were measured before treatment and at 1 d,1 wk,1 and 3 mo after treatment. RESULTS:A total of 46 patients(46 eyes)with BRVO-ME were included,comprising 21 eyes in the ischemic group(7 males,14 females;mean age 55.81±10.36 y)and 25 eyes in the non-ischemic group(11 males,14 females;mean age 54.84±9.81 y).At 3 mo after treatment,BCVA(LogMAR)in the non-ischemic group was superior to that in the ischemic group(0.19±0.19 vs 0.38±0.27,P=0.009).Analysis of CMT changes showed that the reduction amplitude in the ischemic group was significantly greater than that in the non-ischemic group at both 1 and 3 mo after treatment(all P<0.05).Blood flow densities in the whole,parafoveal,and perifoveal regions of the superficial capillary plexus(SCP),as well as in the whole and perifoveal regions of the deep capillary plexus(DCP),were significantly lower in ischemic patients than in non-ischemic patients,while blood flow density in the foveal region of DCP was significantly higher in the ischemic group(all P<0.05). CONCLUSION:Ranibizumab is effective for both types of patients.Non-ischemic patients have a better long-term visual prognosis,and the advantage may be related to better blood flow perfusion patterns in specific areas 3 mo after treatment.Monitoring changes in blood flow density in these areas can help provide personalized treatment for patients.